Description
Ecsemevista (Exemestane) Coated Tablets 25 mg. №30
Ingredients:
Each coated tablet contains 25 mg of exemestane as the active ingredient.
Mechanism of Action:
Exemestane, the active ingredient in Ecsemevista, is an aromatase inhibitor. It works by reducing the production of estrogen in the body, thereby inhibiting the growth of estrogen-sensitive breast cancer cells.
Pharmacological Properties:
Exemestane belongs to the class of drugs known as aromatase inhibitors. It selectively inhibits the aromatase enzyme, which is responsible for converting androgens into estrogens. By reducing estrogen levels, exemestane helps in the treatment of hormone-sensitive breast cancer.
Indications for Use:
Ecsemevista (exemestane) is indicated for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer. It is used to reduce the risk of cancer recurrence following initial treatment.
Contraindications:
Ecsemevista should not be used in individuals who are pregnant, breastfeeding, or have a known hypersensitivity to exemestane. It is important to discuss any existing medical conditions or allergies with a healthcare provider before starting treatment.
Side Effects:
Common side effects of Ecsemevista may include hot flashes, fatigue, joint pain, and headache. In some cases, more serious side effects such as bone fractures or changes in lipid levels may occur. Patients should report any unusual symptoms to their healthcare provider.
Usage Instructions:
The recommended dosage of Ecsemevista is one 25 mg tablet taken orally once daily after a meal. The tablet should be swallowed whole with a glass of water and should not be crushed or chewed.
Benefits Compared to Analogues:
Ecsemevista has shown superior efficacy in reducing the risk of breast cancer recurrence compared to other adjuvant therapies such as tamoxifen. Its mechanism of action as an aromatase inhibitor provides a targeted approach to hormone-sensitive breast cancer treatment.
Suitable Patient Groups:
Ecsemevista is specifically designed for postmenopausal women with estrogen-receptor positive early breast cancer. It is not recommended for use in men, children, or premenopausal women. Elderly patients may require dose adjustments based on their overall health status.
Storage and Shelf Life:
- Store Ecsemevista at room temperature away from moisture and heat.
- Keep the tablets out of reach of children and pets.
Packaging Description:
Each package of Ecsemevista contains 30 coated tablets, with each tablet individually sealed for protection. The packaging is designed to maintain the integrity and potency of the medication until the expiration date.
Clinical Evidence and Proven Effectiveness:
Exemestane has been extensively studied in clinical trials for its efficacy in the adjuvant treatment of breast cancer. Clinical studies have shown that exemestane significantly improves disease-free survival in postmenopausal women with early breast cancer compared to tamoxifen. A study published in the New England Journal of Medicine highlighted the benefits of exemestane in reducing the risk of cancer recurrence.
